These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 11060694)

  • 1. Adenosine deaminase deficiency as the first target disorder in gene therapy.
    Onodera M; Sakiyama Y
    Expert Opin Investig Drugs; 2000 Mar; 9(3):543-9. PubMed ID: 11060694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Transplantation of genetically modified cells in the treatment of children with SCID: great hopes and recent disappointments].
    Smogorzewska EM; Weinberg KI; Kohn DB
    Med Wieku Rozwoj; 2003; 7(1):27-34. PubMed ID: 13130167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
    Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
    Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID.
    Bordignon C; Mavilio F; Ferrari G; Servida P; Ugazio AG; Notarangelo LD; Gilboa E; Rossini S; O'Reilly RJ; Smith CA
    Hum Gene Ther; 1993 Aug; 4(4):513-20. PubMed ID: 8399494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning.
    Otsu M; Yamada M; Nakajima S; Kida M; Maeyama Y; Hatano N; Toita N; Takezaki S; Okura Y; Kobayashi R; Matsumoto Y; Tatsuzawa O; Tsuchida F; Kato S; Kitagawa M; Mineno J; Hershfield MS; Bali P; Candotti F; Onodera M; Kawamura N; Sakiyama Y; Ariga T
    J Clin Immunol; 2015 May; 35(4):384-98. PubMed ID: 25875699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrovirus mediated gene transfer as therapy for adenosine deaminase (ADA) deficiency.
    Ramsey WJ; Mullen CA; Blaese RM
    Leukemia; 1995 Oct; 9 Suppl 1():S70. PubMed ID: 7475319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID.
    Aiuti A; Brigida I; Ferrua F; Cappelli B; Chiesa R; Marktel S; Roncarolo MG
    Immunol Res; 2009; 44(1-3):150-9. PubMed ID: 19224139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy for adenosine deaminase deficiency.
    Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation and alternatives for adenosine deaminase deficiency.
    Gaspar HB
    Immunol Allergy Clin North Am; 2010 May; 30(2):221-36. PubMed ID: 20493398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
    Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
    J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency.
    Onodera M; Ariga T; Kawamura N; Kobayashi I; Ohtsu M; Yamada M; Tame A; Furuta H; Okano M; Matsumoto S; Kotani H; McGarrity GJ; Blaese RM; Sakiyama Y
    Blood; 1998 Jan; 91(1):30-6. PubMed ID: 9414266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
    Ferrua F; Aiuti A
    Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug evaluation: ADA-transduced hematopoietic stem cell therapy for ADA-SCID.
    Taupin P
    IDrugs; 2006 Jun; 9(6):423-30. PubMed ID: 16752313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency.
    Silver JN; Elder M; Conlon T; Cruz P; Wright AJ; Srivastava A; Flotte TR
    Hum Gene Ther; 2011 Aug; 22(8):935-49. PubMed ID: 21142972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for adenosine deaminase severe combined immune deficiency-An unexpected journey of four decades.
    Kohn DB
    Immunol Rev; 2024 Mar; 322(1):148-156. PubMed ID: 38033164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.
    Montiel-Equihua CA; Thrasher AJ; Gaspar HB
    Curr Gene Ther; 2012 Feb; 12(1):57-65. PubMed ID: 22348551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
    Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
    J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.